Updated NCCN Guidelines Now Include Zanubrutinib for WM Updated NCCN Guidelines Now Include Zanubrutinib for WM

The new second-generation BTK inhibitor zanubrutinib is a preferred regimen for the treatment of symptomatic Waldenstrom ' s macroglobulinemia.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news